Bedrijfsoverzicht
Cryo-Cell International, Inc. is a specialized entity within the healthcare sector, specifically operating in the medical care facilities industry, where it provides cellular processing and cryogenic storage services. The company focuses exclusively on cord blood and cord tissue cryopreservation within the United States market, offering these preservation solutions primarily for family use and the collection of umbilical cord blood and tissue stem cells. As a publicly traded company with the ticker symbol CCEL, the firm operates with a market capitalization of $27.95M and employs a workforce of 72 individuals to support its operational capabilities. The annual revenue generated over the trailing twelve months amounts to $31.57M, figures that indicate a small-cap status typical for niche medical service providers that serve a specialized segment of the healthcare economy. This valuation and revenue scale suggest that the company maintains a focused business model, relying on recurring storage fees and collection services rather than the broad revenue streams found in larger healthcare conglomerates, thereby positioning it as a specialized player with limited geographic and product diversification.
Financiële gezondheid
The company's financial performance over the trailing twelve months shows a revenue of $31.57M, while the net income stands at a loss of $-2,429,385, and the EBITDA is reported at $1.47M. The significant gap between the positive revenue of $31.57M and the substantial net loss of $-2,429,385 reveals a cost structure where operating expenses, likely driven by high fixed costs in cryogenic storage infrastructure and R&D, far exceed the gross profits generated from services. Despite the net loss, the company generated positive free cash flow of $580,321, which indicates a degree of financial flexibility allowing the business to fund operations and capital expenditures without immediate reliance on external equity financing or debt covenants. The margin profile presents a mixed picture, with a gross margin of 62.8% suggesting efficient production costs relative to revenue, contrasted sharply by an operating margin of -50.6% and a profit margin of -7.7% that highlight significant overhead burdens. The balance sheet displays $3.30M in cash against $11.56M in debt, a situation that must be viewed alongside a debt-to-equity ratio of N/A, indicating a leveraged position where debt obligations exceed available cash reserves. Liquidity is constrained as evidenced by a current ratio of 0.59, which signifies that current assets are insufficient to cover current liabilities without liquidating long-term assets or securing new financing. Return on Equity is listed as N/A due to the equity dynamics, while the return on assets is a modest 0.5%, revealing that management effectiveness in generating profit from the asset base is currently limited by the net loss position.
Waarderingsbeoordeling
Valuation metrics for Cryo-Cell International, Inc. include a trailing P/E ratio of N/A due to the lack of positive earnings, and a forward P/E of 43.38 that implies market expectations of future profitability to justify the current price. The difference between a non-existent trailing P/E and a forward P/E of 43.38 suggests that the market is pricing in a future earnings trajectory that has not yet materialized in historical financial statements. The price-to-book ratio is negative at -1.50, which indicates that the market values the company at less than its book value, a common characteristic for firms with accumulated losses or specific asset valuation adjustments. Alternative valuation multiples provide further context, with a price-to-sales ratio of 0.89 and an EV/EBITDA of 24.68, suggesting that investors are valuing the firm primarily on its revenue generation and EBITDA potential rather than current profitability. Price momentum is bounded by a 52-week high of $6.35 and a 52-week low of $2.72, placing the current trading price within a range that reflects high volatility and sensitivity to sector-specific sentiment. The beta value of 0.63 indicates that the stock price exhibits lower volatility relative to the broader market, moving less dramatically than the general index during periods of market fluctuation.
Growth & Income
Growth dynamics for the company show a revenue growth year-over-year of -2.3%, while earnings growth year-over-year is N/A due to the negative earnings history. The decline in revenue growth of -2.3% combined with N/A earnings growth implies that the business is currently facing headwinds in customer acquisition or retention that are preventing the translation of revenue stability into profitability. Regarding income, the company reports a dividend yield of 17.3% and a payout ratio of 3962.9%, figures that indicate the dividend is mathematically unsustainable given the net loss and negative earnings base. The extremely high payout ratio of 3962.9% suggests that the dividend is being paid from cash reserves or other non-earnings sources rather than distributed profits, which poses a long-term risk to income stability for shareholders. The overall growth and income profile is characterized by negative revenue momentum, a lack of profitability, and a dividend structure that relies on capital depletion rather than earnings coverage, presenting a challenging environment for income-focused investors.